There was a mistake in Table 1 as published. There is an error in Table 1 regarding the FIGO Stages (2014) for Stages IA and IIB. The formatting of the term “Other” in Table 1 is incorrect. The correct terms should be Stages “IIIA and IIIB”, and the formatting of the term “Other” should be consistent with that of “Endometrioid”. The corrected Table 1 appears below.
Table 1.
Preoperative basic characteristic data of ovarian cancer patients.
| Characteristics | Bowel resection group (n=101) | Bowel tumor stripping group (n=154) | P value |
|---|---|---|---|
| Age (y) | 56.24 ± 9.51 | 54.90 ± 9.15 | 0.261 |
| FIGO Stage (2014) | 0.021* | ||
| IIIA | 5 (4.95) | 10 (6.49) | |
| IIIB | 5 (4.95) | 20 (12.99) | |
| IIIC | 70 (69.31) | 108 (70.13) | |
| IV | 21 (20.79) | 16 (10.39) | |
| Pathology | 0.097 | ||
| Endometrioid | 4 (4.0) | 18 (11.7) | |
| Mucinous | 1 (1.0) | 2 (1.3) | |
| Serous | 88 (87.1) | 114 (74.0) | |
| High grade | 86 (97.73) | 109 (95.61) | |
| Low grade | 2 (2.27) | 5 (4.39) | |
| Clear Cell | 0 (0) | 1 (0.6) | |
| Mixed | 2 (2.0) | 6 (3.1) | |
| Serous Cystadenocarcinoma | 3 (3.0) | 2 (2.0) | |
| Others | 3 (3.0) | 11 (7.1) | |
| Hospital Stays (d) | 22.77 ± 9.54 | 19.40 ± 5.77 | 0.001* |
| Surgical Type | 0.298 | ||
| PDS | 75 (74.26) | 105 (68.18) | |
| IDS | 26 (25.74) | 49 (31.82) | |
| NACT Cycles | 0.521 | ||
| 1-3 | 19 (73.08) | 39 (79.59) | |
| ≥4 | 7 (26.92) | 10 (20.41) |
*P < 0.05, indicating a statistically significant difference.
A correction has been made to the section Materials and methods, “Patients”, Paragraph 5. The phrase “3orksycles” in this paragraph contains an error; the correct wording is “3–4 cycles”:
“All patients received a liquid diet starting 3 days before surgery for bowel preparation and took oral laxatives 1 day preoperatively. According to current guidelines, NACT was indicated for patients with advanced epithelial ovarian cancer who were not candidates for immediate surgery due to extensive disease and high perioperative risk. NACT consisted of platinum-based combination chemotherapy, typically paclitaxel plus carboplatin, administered every 3 weeks for 3–4 cycles. Patients who underwent interval debulking surgery (IDS) and achieved R0 resection received at least 3 cycles of adjuvant chemotherapy postoperatively. Patients who underwent primary debulking surgery (PDS) received postoperative platinum-based first-line chemotherapy, either alone or in combination with paclitaxel, every 3–4 weeks for 6–8 cycles. The follow-up period for all patients ranged from 2 to 98 months”.
The original version of this article has been updated.
Footnotes
Edited and reviewed by: Alberto Farolfi, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.